Sunil Rayan, MD
Vascular Surgery · Encinitas, CANPI 1174606016
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,800 of the $26,530 with a category attached, or 63.3%. Endologix LLC accounts for 78.1% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $7,138 and has fallen 51.5% since, to $3,459 in 2025.
Across 206 payments — averaging $128.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endologix LLC$21K
- Medtronic$2K
- Silk Road Medical, Inc.$1K
- W. L. Gore & Associates, Inc.$603
- Boston Scientific$558
- Angiodynamics, Inc.$349
- plus $1K from 24 others
What the payments were for
- Consulting fees$16,80063%
- Food & beverage$9,68437%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endologix LLC | 41 | $20,729 |
| Medtronic(2 entities) | 62 | $1,801 |
| Silk Road Medical, Inc. | 18 | $1,088 |
| W. L. Gore & Associates, Inc. | 14 | $603 |
| Boston Scientific | 14 | $558 |
| Angiodynamics, Inc. | 7 | $349 |
| Abbott | 4 | $175 |
| Cook Medical LLC | 3 | $172 |
| Titan Spine, LLC | 1 | $106 |
| Cardiovascular Systems Inc. | 4 | $99 |
| Bard Peripheral Vascular, Inc. | 4 | $92 |
| Inari Medical, Inc. | 3 | $89 |
| Tactile Systems Technology Inc | 5 | $77 |
| Johnson & Johnson | 2 | $70 |
| Microtransponder, Inc. | 1 | $63 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $54 |
| BD | 1 | $49 |
| Penumbra, Inc. | 2 | $46 |
| Bolton Medical Inc | 2 | $44 |
| Pfizer | 3 | $42 |
| Myovant Sciences Inc. | 3 | $41 |
| Philips North America LLC | 2 | $40 |
| Medline Industries LP | 2 | $35 |
| Blue Earth Diagnostics | 1 | $22 |
| Cordis US CORP. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Chiesi USA, Inc. | 1 | $15 |
| Neotract Inc. | 1 | $14 |
| Biotissue Holdings Inc. | 1 | $13 |
| Amniox Medical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AFX$9,156
- Ovation$8,404
- Alto Abdominal Stent Graft System$7,997
- AFX2 Bifurcated Endograft System$3,571
- ENROUTE Transcarotid Neuroprotection System$1,112
- ENDOCROSS Device$664
- Torus Stent Graft System$664
- ENROUTE Transcarotid Stent$535
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$378
- ENHANCE Transcarotid Peripheral Access Kit$374
- Ovation iX Iliac Stent Graft$271
- Auryon Laser System 100-120 Vac$245
- ENROUTE Transcarotid Stent System$199
- ENROUTE 0.014 Guidewire$199
- nanoLOCK-C$179
- ENDURANT IIS$176
- GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis$150
- Cook Medical IAA$120
- ABSOLUTE PRO$114
- ANTERALIGN SPINAL SYSTEM WITH TITAN NANOLOCK SURFACE TECHNOLOGY$109
How this compares
$26,530 in reported general payments places this provider in the 85th percentile of 519 vascular surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 23 | $13,253 |
| XareltoRivaroxaban | 11 | $6,952 |
| ClopidogrelClopidogrel Bisulfate | 152 | $1,167 |
| Tamsulosin Hcl | 44 | $393 |
| Finasteride | 24 | $277 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 25 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $42 | $13,25323 claims |
| Johnson & JohnsonXarelto | $70 | $6,95211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 519 vascular surgery providers in California.
Other vascular surgery in Encinitas
- Son DuongFountain Valley$503K
- Venita ChandraPalo Alto$488K
- Sukgu HanLos Angeles$477K
- Leigh Ann ObanionFresno$469K
- Trevor DerderianRancho Mirage$359K
- Karthikeshwar KasirajanPalo Alto$349K
- Johnathon RolloLos Angeles$337K
- Melissa LojaFairfield$272K
- Jason LeePalo Alto$228K
- John LaneSan Diego$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.